Movement Alert|Thermo Fisher Scientific Falls 3.05% in Regular Trading, Evercore ISI Cuts Target Price Amid Sector Weakness

Market Focus07-06

On July 6, Thermo Fisher Scientific declined 3.05% in regular trading, trading at approximately $509.69/share, with turnover of $164 million. The decline was driven by a combination of an analyst target price reduction and broad weakness across the life sciences tools sector.

Evercore ISI lowered its price target on Thermo Fisher Scientific to $570 from $575 while maintaining its Outperform rating. The stock currently carries a consensus mean price target of $595 with an overweight average rating. At the sector level, life sciences tools and services stocks faced broad selling pressure, with peer Danaher declining 3.59% during the same session, highlighting significant sector-wide linkage effects.

The company is scheduled to report next quarterly earnings on July 23 before market open, with analysts expecting adjusted EPS of $5.71. In its most recent quarter, Thermo Fisher beat consensus estimates with adjusted EPS of $5.44 versus the $5.24 estimate, while revenue of $11.005 billion also exceeded the $10.853 billion forecast.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment